as per attachment
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarey Drugs reported FY2026 revenue of Rs 4,722.69 crore (Rs 47,226.90 lakhs), marginally declining from Rs 4,739.43 crore in FY2025. Profit after tax fell slightly to Rs 396.76 lakhs from Rs 402.39 lakhs, while EPS decreased to Rs 1.39 from Rs 1.42. The statutory auditor issued an unmodified (clean) opinion. However, the auditor's report includes an Emphasis of Matter noting that debtor and creditor balances are subject to confirmation and based on management representation, as confirmations from parties were not available. No deviation was reported in utilization of Rs 797.50 lakh funds raised through convertible warrants preferential issue.
The company showed flat-to-slightly negative performance with marginal revenue and profit decline. The auditor's emphasis on unconfirmed debtor/creditor balances raises some concern about balance sheet quality, though the clean audit opinion provides comfort. Shareholders should monitor collections and payable management.